CN115252460A - Acne-removing composition containing antibacterial peptide and preparation method and application thereof - Google Patents
Acne-removing composition containing antibacterial peptide and preparation method and application thereof Download PDFInfo
- Publication number
- CN115252460A CN115252460A CN202210990576.1A CN202210990576A CN115252460A CN 115252460 A CN115252460 A CN 115252460A CN 202210990576 A CN202210990576 A CN 202210990576A CN 115252460 A CN115252460 A CN 115252460A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- acne
- parts
- liquid component
- solid component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 17
- 206010000496 acne Diseases 0.000 title abstract description 60
- 208000002874 Acne Vulgaris Diseases 0.000 title abstract description 59
- 239000000341 volatile oil Substances 0.000 claims abstract description 95
- 239000007788 liquid Substances 0.000 claims abstract description 41
- 239000007787 solid Substances 0.000 claims abstract description 35
- 102000016943 Muramidase Human genes 0.000 claims abstract description 30
- 108010014251 Muramidase Proteins 0.000 claims abstract description 30
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 30
- 108010053775 Nisin Proteins 0.000 claims abstract description 30
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims abstract description 30
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 30
- 229960000274 lysozyme Drugs 0.000 claims abstract description 30
- 239000004325 lysozyme Substances 0.000 claims abstract description 30
- 235000010297 nisin Nutrition 0.000 claims abstract description 30
- 239000004309 nisin Substances 0.000 claims abstract description 30
- 239000002904 solvent Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 11
- 238000004806 packaging method and process Methods 0.000 claims abstract description 8
- 241000196324 Embryophyta Species 0.000 claims description 26
- 230000003255 anti-acne Effects 0.000 claims description 21
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 20
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 14
- 239000001585 thymus vulgaris Substances 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 12
- 229930002330 retinoic acid Natural products 0.000 claims description 12
- 229960001727 tretinoin Drugs 0.000 claims description 12
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 10
- 229960004926 chlorobutanol Drugs 0.000 claims description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 10
- -1 retinoic acid ester Chemical class 0.000 claims description 10
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 9
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 9
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims description 9
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 9
- 229960003237 betaine Drugs 0.000 claims description 9
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 239000003906 humectant Substances 0.000 claims description 7
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000003410 keratolytic agent Substances 0.000 claims description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 5
- 244000061520 Angelica archangelica Species 0.000 claims description 5
- 229920000832 Cutin Polymers 0.000 claims description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 claims description 5
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- YRJKYHIIYRGTCC-UHFFFAOYSA-M potassium;2-hydroxy-4-methoxybenzoate Chemical compound [K+].COC1=CC=C(C([O-])=O)C(O)=C1 YRJKYHIIYRGTCC-UHFFFAOYSA-M 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 235000017803 cinnamon Nutrition 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 240000002657 Thymus vulgaris Species 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 244000166124 Eucalyptus globulus Species 0.000 claims 2
- 240000000950 Hippophae rhamnoides Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 9
- 230000007547 defect Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000035699 permeability Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 23
- 239000000047 product Substances 0.000 description 20
- 244000004281 Eucalyptus maculata Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241000246358 Thymus Species 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 241000186427 Cutibacterium acnes Species 0.000 description 10
- 229940055019 propionibacterium acne Drugs 0.000 description 9
- 241000229143 Hippophae Species 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 208000020154 Acnes Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241000213006 Angelica dahurica Species 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004125 Interleukin-1alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000219927 Eucalyptus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229940059958 centella asiatica extract Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940051921 muramidase Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 230000036619 pore blockages Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940098386 usnea barbata extract Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an acne-removing composition containing antibacterial peptide, a preparation method and application thereof, wherein the acne-removing composition comprises a solid component and a liquid component which are independently packaged; the solid component comprises lysozyme and nisin; the liquid component comprises plant essential oil, solubilizer and water. According to the invention, the lysozyme and nisin are creatively found to be capable of synergistically playing antibacterial and anti-inflammatory effects after being compounded, so that the plant essential oil has remarkable effects of removing acne and repairing acne mark skin, and the plant essential oil with strong permeability can assist in promoting the antibacterial and anti-inflammatory effects. The composition adopts a mode of independently packaging lysozyme and nisin, can avoid the defect that lysozyme and nisin are unstable and easy to inactivate in a water-soluble state, and prolongs the effective period of the product.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and relates to an anti-acne composition containing antibacterial peptide, and a preparation method and application thereof.
Background
Acne generally refers to acne, which is a chronic inflammatory skin disease of pilosebaceous units, mainly occurs to teenagers, has great influence on psychology and social interaction of the teenagers, and can be naturally relieved or healed after adolescence. The clinical manifestations are marked by the skin lesions of various shapes, such as acne, papule, pustule, and nodule, which are easy to be developed on the face. Acne occurs in close relation to factors such as hyperseborrhea, blockage of pilosebaceous ducts, bacterial infection and inflammatory reactions. After adolescence, the level of androgen, particularly testosterone, in a human body is rapidly increased, the development of sebaceous glands is promoted, and a large amount of sebum is produced. If the grease can not be discharged in time to block pores, the anaerobic bacterium propionibacterium acnes can be greatly proliferated to destroy epidermal cells to trigger inflammatory reaction.
Propionibacterium acnes is a species of Propionibacterium, a causative bacterium of acne. Gram-positive bacilli, also called acne bacilli and propionibacterium acnes, are named because fermentation of glucose to produce propionic acid, and are the main bacteria causing whelk. Genomic studies have shown that several genes of this bacterium can produce several proteins that break down the enzymes and immunogenicity of skin tissues.
The topical medicinal products for removing acne include retinoic acid, benzoyl peroxide, and antibiotics. However, retinoic acid increases the photosensitivity of the skin, causing the skin to become red; benzoyl peroxide has certain irritation, and individual patients can have reactions such as skin redness and desquamation; antibiotics can cause bacterial drug resistance, and the treatment course is not too long. Compared with external pharmaceuticals, the acne-removing skin care product, especially the skin care product with natural sources, has the advantages of skin irritation or safety and is more easily accepted by consumers, and in recent years, the acne-removing skin care product with natural sources is used as a main mode for removing acnes.
For example, CN113750015A discloses an acne removing composition with acne mark removing and scar removing effects, which comprises scutellaria root extract, phellodendron bark extract, coptis root extract and centella asiatica extract. The composition has effects of removing acne mark, removing acne scar, controlling oil and removing acne.
For example, CN107737033A discloses a composition for rapidly removing acne and acne marks, comprising the following components: 1.2-1.8 parts of salicylic acid; 2-2.77 parts of arginine; 0.5-2 parts of usnea barbata extract; 1-10 parts of glabridin liposome; 0.03-0.1 part of O-cymene-5 alcohol; 1-12 parts of other acne-removing functional components; and 75-90 parts of other base materials. The composition has excellent acne removing effect, and also has good acne mark preventing and removing effects.
However, the strategy for safely and effectively removing acne and repairing acne mark skin disclosed in the prior art is limited, and after a great deal of research work is carried out in the field of acne-removing skin care products, the lysozyme and nisin are found to have the effects of well inhibiting the proliferation of propionibacterium acnes and reducing skin inflammation after being compounded, and simultaneously, the skin is not stimulated, so that the acne-removing skin care product is completed.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide an anti-acne composition containing antibacterial peptide, and a preparation method and application thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the invention provides an anti-acne composition containing antibacterial peptides, which comprises a solid component and a liquid component which are packaged separately; the solid component comprises lysozyme and nisin; the liquid component comprises plant essential oil, solubilizer and water.
Wherein lysozyme is also called muramidase or N-acetylmuramyl glycan hydrolase, is an alkaline enzyme widely existing in eggs, human saliva, tears, milk and the like, and can effectively hydrolyze peptidoglycan of bacterial cell walls, so that insoluble mucopolysaccharide in the cell walls can be decomposed into soluble peptidoglycan, resulting in cell death. Nisin is a polypeptide antibiotic secreted by streptococcus lactis, consists of thirty-four amino acids, takes yeast powder as a raw material, and is obtained by fermenting the streptococcus lactis under certain conditions.
According to the invention, the lysozyme and nisin are creatively found to be capable of synergistically playing antibacterial and anti-inflammatory effects after being compounded, so that the plant essential oil has remarkable effects of removing acne and repairing acne mark skin, and the plant essential oil with strong permeability can assist in promoting the antibacterial and anti-inflammatory effects. The composition adopts a mode of independently packaging lysozyme and nisin, can avoid the defect that lysozyme and nisin are unstable and easy to inactivate in a water-soluble state, and prolongs the effective period of the product.
Preferably, the solid component comprises 0.1 to 5 parts of lysozyme and 0.1 to 5 parts of nisin by weight; the liquid component comprises, by weight, 0.01-0.2 part of plant essential oil, 0.1-1 part of solubilizer and 90-98 parts of water.
When the components in the composition are compounded according to the specific weight proportion mode, the composition has more remarkable effects of resisting bacteria, diminishing inflammation and repairing acne marks on skin.
The weight parts of the lysozyme can be selected from 0.1 part, 0.3 part, 0.5 part, 0.8 part, 1 part, 1.5 part, 2 parts, 2.5 parts, 3 parts, 4 parts, 5 parts and the like.
The weight parts of the nisin can be selected from 0.1 part, 0.3 part, 0.5 part, 0.8 part, 1 part, 1.5 part, 2 parts, 2.5 parts, 3 parts, 4 parts, 5 parts and the like.
The plant essential oil can be selected from 0.01 part, 0.02 part, 0.04 part, 0.08 part, 0.1 part, 0.12 part, 0.14 part, 0.16 part, 0.18 part, 0.2 part and the like in parts by weight.
The solubilizer can be selected from 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part and the like in parts by weight.
The weight parts of the water can be selected from 90 parts, 91 parts, 92 parts, 93 parts, 94 parts, 95 parts, 96 parts, 97 parts, 98 parts and the like.
Other specific point values within the above numerical ranges can be selected, and are not described in detail herein.
Preferably, the plant essential oil comprises any one or a combination of at least two of eucalyptus essential oil, rosemary essential oil, thyme essential oil, angelica essential oil, sea buckthorn fruit essential oil or cinnamon essential oil; the combination of at least two of the essential oils is, for example, the combination of eucalyptus essential oil and rosemary essential oil, the combination of rosemary essential oil and thyme essential oil, the combination of angelica essential oil and seabuckthorn fruit essential oil, and the like, and any combination mode can be selected, so that the details are not repeated.
The plant essential oils in the composition according to the invention are preferably of the above-mentioned types of essential oils, which have a better antibacterial and anti-inflammatory action of the co-lysozyme and nisin, more preferably in the following combinations.
Preferably, the plant essential oil comprises a combination of eucalyptus essential oil, rosemary essential oil and thyme essential oil.
Preferably, the liquid component further comprises a glycyrrhizic acid derivative.
The glycyrrhizic acid derivative has good anti-inflammatory and skin soothing effects for patients, and the glycyrrhizic acid derivative is further added into the composition disclosed by the invention, so that the effects of removing acnes and acne marks can be improved.
Preferably, the glycyrrhizic acid derivative comprises any one of dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, diammonium glycyrrhizinate, disodium glycyrrhizinate, zinc glycyrrhetinate or glycyrrhetinate stearate or a combination of at least two of the dipotassium glycyrrhizinate, the monoammonium glycyrrhizinate, the diammonium glycyrrhizinate, the disodium glycyrrhizinate, the zinc glycyrrhetinate and the glycyrrhetinate stearate; the combination of at least two of the compounds, such as the combination of dipotassium glycyrrhizinate and monoammonium glycyrrhizinate, the combination of diammonium glycyrrhizinate and disodium glycyrrhizinate, the combination of zinc glycyrrhetinate and glycyrrhetinate stearate, and the like, can be selected in any combination mode, and are not repeated herein.
Preferably, the liquid component further comprises a keratolytic agent.
The keratolytic agent can make keratinocyte soft and separate to fall off, prevent pore blockage, control oil secretion, inhibit acne, and has good adjuvant therapeutic effect on acne muscle. The cutin debonding agent can improve the effects of removing acnes and acne marks by further adding the cutin debonding agent.
Preferably, the keratolytic agent includes one or a combination of at least two of hydroxyppinacolone retinoic acid ester, potassium methoxysalicylate, and tartaric acid, for example, a combination of tartaric acid and potassium methoxysalicylate, a combination of potassium methoxysalicylate and hydroxyppinacolone retinoic acid ester, and any other combination mode can be selected, and is not described herein again. More preferably hydroxy pinacolone retinoic acid ester.
Preferably, the liquid component further comprises a humectant.
Preferably, the humectant comprises any one or a combination of at least two of glycerin, propylene glycol, 1,3 butylene glycol or methyl propylene glycol; the combination of at least two of the above-mentioned compounds, such as the combination of glycerin and propylene glycol, the combination of propylene glycol and 1, 3-butylene glycol, the combination of 1, 3-butylene glycol and methyl propylene glycol, etc., can be selected in any combination manner, and will not be described in detail herein.
Preferably, the solid component further comprises betaine. Betaine exerts moisturizing and dispersion promoting effects.
Preferably, the mass ratio of the solid component to the liquid component is (0.5-5): (95-99.5), for example, 0.5.
Preferably, the solid component comprises 0.1-5 parts of lysozyme, 0.1-5 parts of nisin and 90-99 parts of betaine by weight.
The weight parts of the betaine can be selected from 99 parts, 99 parts and 99 parts 99 parts, 99 parts 99 parts, 99 parts and the like.
Preferably, the liquid component comprises, by weight, 0.01-0.2 part of plant essential oil, 0.05-0.5 part of glycyrrhizic acid derivative, 0.01-0.1 part of cutin debonding agent, 2-10 parts of humectant, 0.1-1 part of solubilizer and 90-98 parts of water.
The glycyrrhizic acid derivative can be selected from 0.05 part, 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part and the like in parts by weight.
The cutin debonding agent can be selected from 0.01 part, 0.02 part, 0.03 part, 0.04 part, 0.05 part, 0.06 part, 0.07 part, 0.08 part, 0.09 part, 0.1 part and the like in parts by weight.
The humectant can be selected from 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts and the like in parts by weight.
Other specific point values within the above numerical range can be selected, and are not described in detail herein.
Preferably, the liquid component further includes any one or a combination of at least two of chlorobutanol, phenoxyethanol, parabens or ethylhexyl glycerol, the combination of at least two of the chlorobutanol and phenoxyethanol can be selected, and any other combination mode can be selected, which is not repeated herein. Chlorobutanol is preferred.
The chlorobutanol has local analgesic and anesthetic effects, relieves the skin of a human, and is better in use feeling and more comfortable for a patient, and the chlorobutanol is more preferable.
In a second aspect, the present invention provides a method for preparing an anti-acne composition containing antibacterial peptide according to the first aspect, the method comprising:
uniformly mixing all the raw materials of the solid component; premixing plant essential oil and a solubilizer, and uniformly mixing the premixed plant essential oil and the solubilizer with other raw materials of liquid components; and independently packaging the solid component and the liquid component to obtain the product.
In a third aspect, the invention provides a method for using the anti-acne composition containing antibacterial peptide according to the first aspect, wherein the method for using the composition comprises the following steps: and mixing the independently packaged solid component and the liquid component until the solid component is completely dissolved, and directly using the mixed liquid.
In a fourth aspect, the invention provides an application of the anti-acne composition containing antibacterial peptide according to the first aspect in preparing a skin care product or an external medicinal preparation with an anti-acne effect.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively discovers that the lysozyme and the nisin can synergistically play antibacterial and anti-inflammatory effects after being compounded, the plant essential oil has remarkable effects on removing acne and repairing acne mark skin, and the plant essential oil with strong permeability can assist in promoting the antibacterial and anti-inflammatory effects. The composition adopts a mode of independently packaging lysozyme and nisin, can avoid the defect that lysozyme and nisin are unstable and easy to inactivate in a water-soluble state, and prolongs the effective period of the product. The composition provided by the invention can improve the effects of removing acnes and acne marks by further adding glycyrrhizic acid derivatives and/or keratolytic agents.
Detailed Description
In order to further illustrate the technical means and effects of the present invention, the technical solutions of the present invention are further described below with reference to the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
The following examples and comparative examples refer to the following sources of raw materials:
| starting materials | Purchase source | Model number |
| Lysozyme and its preparation method | Guangzhou Jinbao Biotech Co Ltd | Lysozyme |
| Nisin | Suzhou Fulaide Biotechnology Ltd | Nisin |
| Eucalyptus oil | Zhangzhou Yuzhentang Biological Technology Co., Ltd. | Eucalyptus single-component essential oil |
| Rosemary essential oil | Zhangzhou Yuzhentang Biological Technology Co., Ltd. | Rosemary single component essential oil |
| Thyme essential oil | Zhangzhou Yuzhentang Biological Technology Co., Ltd. | Bailixian essential oil |
| Essential oil of Chinese angelica | Zhangzhou Yuzhentang Biological Technology Co., Ltd. | Chinese angelica single component essential oil |
| Seabuckthorn fruit essential oil | Zhangzhou Yuzhentang Biological Technology Co., Ltd. | Fructus Hippophae Single recipe essential oil |
| Cinnamon essential oil | Jiangxi Hengcheng Natural Fragrance Oil Co.,Ltd. | Cinnamon oil |
| Potassium methoxysalicylate | Zhuhaibairui pharmaceutical science and technology Co Ltd | 4-Methoxysalicylic acid potassium salt |
| Hydroxy pinacolone retinoic acid ester | GUANGZHOU TROJAN PHARMATECH Co.,Ltd. | CG HPR |
| CO40 | BASF CHINA Co.,Ltd. | Cremophor CO 40 |
| TW60 | Suzhou Yuan Tai run chemical Co., ltd | Tween 60 |
| Fruit acid | Jiangsu Caosheng Biotech Co., ltd | Fruit acid 99% |
Example 1
The embodiment provides an acne removing composition, which comprises a solid component and a liquid component which are independently packaged in a mass ratio of 5;
the solid components comprise the following components in parts by weight: 2 parts of lysozyme, 3 parts of nisin and 95 parts of betaine; the liquid components comprise the following components in parts by weight: 0.5 part of eucalyptus essential oil, 0.5 part of rosemary essential oil, 0.5 part of thyme essential oil, 0.2 part of dipotassium glycyrrhizinate, 0.2 part of monoammonium glycyrrhizinate, 0.01 part of hydroxy pinacolone retinoic acid ester, 0.1 part of chlorobutanol, 4% of glycerol, 3% of propylene glycol, 1% of 1, 3% of butanediol, 0.5 part of solubilizer TW and 90 parts of deionized water.
The preparation method comprises the following steps:
uniformly mixing all the raw materials of the solid component; premixing plant essential oil and a solubilizer, and uniformly mixing the premixed plant essential oil and the solubilizer with other raw materials of liquid components; and independently packaging the solid component and the liquid component to obtain the product.
Example 2
The embodiment provides an acne-removing composition, which comprises a solid component and a liquid component which are packaged independently and have a mass ratio of 2;
the solid components comprise the following components in parts by weight: 4 parts of lysozyme, 1 part of nisin and 95 parts of betaine; the liquid components comprise the following components in parts by weight: 0.5 part of eucalyptus essential oil, 0.5 part of angelica essential oil, 0.5 part of seabuckthorn fruit essential oil, 0.1 part of disodium glycyrrhizinate, 0.1 part of diammonium glycyrrhizinate, 0.05 part of hydroxy pinacolone retinoic acid ester, 0.3 part of chlorobutanol, 2% of glycerol, 2% of methyl propylene glycol, 1% of 1,3 butylene glycol, 400.2 parts of solubilizer CO and 90 parts of deionized water.
The preparation method comprises the following steps:
uniformly mixing all the raw materials of the solid component; premixing plant essential oil and a solubilizer, and uniformly mixing the premixed plant essential oil and the solubilizer with other raw materials of liquid components; and independently packaging the solid component and the liquid component to obtain the product.
Example 3
The embodiment provides an acne-removing composition, which comprises a solid component and a liquid component which are independently packaged and have a mass ratio of 1;
the solid components comprise the following components in parts by weight: 1 part of lysozyme, 3 parts of nisin and 96 parts of betaine; the liquid components comprise the following components in parts by weight: 0.4 part of cinnamon essential oil, 0.4 part of rosemary essential oil, 0.7 part of thyme essential oil, 0.1 part of zinc glycyrrhetinate, 0.1 part of glycyrrhetinate stearate, 0.05 part of hydroxy pinacolone retinoic acid ester, 0.2 part of chlorobutanol, 2% of glycerol, 2% of methyl propylene glycol, 1% of 1, 3-butanediol, 0.8 part of solubilizer CO40 and 90 parts of deionized water.
The preparation method comprises the following steps:
uniformly mixing all the raw materials of the solid component; premixing plant essential oil and a solubilizer, and uniformly mixing the premixed plant essential oil and the solubilizer with other raw materials of liquid components; and independently packaging the solid component and the liquid component to obtain the product.
Example 4
The present example provides an acne removing composition, which is different from that in example 1 only in that 0.5 part of eucalyptus essential oil, 0.5 part of rosemary essential oil and 0.5 part of thyme essential oil are replaced by 0.75 part of rosemary essential oil and 0.75 part of thyme essential oil, and other components and contents thereof are kept unchanged. The preparation method is the same as in example 1.
Example 5
The present example provides an acne removing composition, which is different from that in example 1 only in that 0.5 part of eucalyptus essential oil, 0.5 part of rosemary essential oil and 0.5 part of thyme essential oil are replaced by 0.75 part of eucalyptus essential oil and 0.75 part of thyme essential oil, and other components and contents thereof are kept unchanged. The preparation method is the same as that of example 1.
Example 6
This example provides an anti-acne composition, which is different from that in example 1 only in that 0.5 part of eucalyptus essential oil, 0.5 part of rosemary essential oil and 0.5 part of thyme essential oil are replaced by 0.75 part of eucalyptus essential oil and 0.75 part of rosemary essential oil, and other components and contents are kept unchanged. The preparation method is the same as that of example 1.
Example 7
This example provides an acne-removing composition, which is different from that in example 1 only in that 0.5 part of eucalyptus essential oil, 0.5 part of rosemary essential oil and 0.5 part of thyme essential oil are replaced by 0.5 part of eucalyptus essential oil, 0.5 part of angelica essential oil and 0.5 part of seabuckthorn fruit essential oil, and other components and contents are kept unchanged. The preparation method is the same as that of example 1.
Example 8
The present example provides an acne removing composition, which is different from that in example 1 only in that 0.2 part of dipotassium glycyrrhizinate and 0.2 part of monoammonium glycyrrhizinate are replaced by 0.4 part of dipotassium glycyrrhizinate, and other components and contents thereof are kept unchanged. The preparation method is the same as in example 1.
Example 9
The present example provides an acne removing composition, which is different from that in example 1 only in that 0.2 part of dipotassium glycyrrhizinate and 0.2 part of monoammonium glycyrrhizinate are replaced by 0.4 part of monoammonium glycyrrhizinate, and other components and contents are kept unchanged. The preparation method is the same as that of example 1.
Example 10
This example provides an acne-removing composition, which is different from that in example 1 only in that 0.01 part of hydroxy pinacolone retinoic acid ester is replaced by 0.01 part of fruit acid, and other components and contents are kept unchanged. The preparation method is the same as in example 1.
Example 11
This example provides an anti-acne composition that differs from example 1 only in that it does not contain the following ingredients: dipotassium glycyrrhizinate 0.2 parts, monoammonium glycyrrhizinate 0.2 parts, and tartaric acid 0.01 parts, and deionized water for the balance. The other components and contents are kept unchanged. The preparation method is the same as that of example 1.
Comparative example 1
The comparative example provides an acne-removing composition, and the formula composition of the acne-removing composition is different from that of example 1 only in that 2 parts of lysozyme and 3 parts of nisin are replaced by 5 parts of lysozyme, and other components and contents of the composition are kept unchanged. The preparation method is the same as in example 1.
Comparative example 2
The comparative example provides an acne-removing composition, and the formula composition of the acne-removing composition is different from that of example 1 only in that 2 parts of lysozyme and 3 parts of nisin are replaced by 5 parts of nisin, and other components and contents are kept unchanged. The preparation method is the same as that of example 1.
The samples of the following test examples were all products obtained by immediately mixing the solid components and the liquid components in the compositions of examples 1 to 11 and comparative examples 1 to 2.
Test example 1
Skin safety test:
the products prepared in examples 1 to 11 were placed in a spot tester, the spot tester with the test substance added thereto was attached to the flexed side of the forearm of a human subject (20) and applied to the skin by gentle pressure with the palm for 24 hours; the skin irritation and sensitization were observed according to table 1 (skin closed patch test skin response grading standard) 30min, 24 hours, and 48 hours after removal of the test substance patch, respectively, and the observation results were recorded.
TABLE 1
The results show that no adverse skin reactions occur in the products of examples 1 to 11, which indicates that the acne-removing composition related to the invention is safe and non-irritant to the skin.
Test example 2
130 female volunteers of vaccinia muscle 15-35 years old were selected, randomized into 13 groups of 10, and 1 product of examples 1-11 and comparative examples 1-2 was used after each night of facial cleansing with consistent pattern of use. The basic skin care product is used for 30 days continuously, and the other basic skin care products are used within 30 days. The volunteers evaluated the irritation and acne-removing effect of the product, and the scoring criteria and grades are as follows:
the results are shown in table 2 (all data are presented as mean):
TABLE 2
| Group of | Irritation property | Acne removing effect |
| Example 1 | 3.9 | 3.6 |
| Example 2 | 3.7 | 3.1 |
| Example 3 | 3.7 | 3.0 |
| Example 4 | 3.8 | 3.3 |
| Example 5 | 3.9 | 3.5 |
| Example 6 | 3.7 | 3.2 |
| Example 7 | 3.8 | 3.2 |
| Example 8 | 3.6 | 3.5 |
| Example 9 | 3.5 | 3.6 |
| Example 10 | 3.1 | 3.7 |
| Example 11 | 3.2 | 3.2 |
| Comparative example 1 | 3.7 | 2.5 |
| Comparative example 2 | 3.8 | 2.8 |
As can be seen from the data in Table 2: the acne-removing composition disclosed by the invention is very excellent in mildness, and very remarkable in acne-removing effect and acne mark repairing effect.
Test example 3
Propionibacterium acnes inhibition assay:
propionibacterium acnes at 1 × 10 8 Each/mL was inoculated in a 96-well plate at 150. Mu.L per well, 150. Mu.L of the sample solutions of examples 1-11 and comparative examples 1-2 was added, and the mixture was incubated at 37 ℃ in an incubator without oxygen for 48 hours with the addition of an equal volume of medium as a blank. The absorbance at 600nm was measured with an ultraviolet spectrophotometer, and the inhibition ratio of Propionibacterium acnes was calculated according to the following formula.
Propionibacterium acnes inhibition = [ (blank control absorbance-experimental group absorbance)/blank control group absorbance ] × 100%
Each group was assayed 3 times in parallel and averaged, with the results shown in table 3:
TABLE 3
As can be seen from the data in Table 3: the acne-removing composition has a very remarkable inhibition effect on propionibacterium acnes, wherein lysozyme and nisin have a synergistic effect on the inhibition of propionibacterium acnes.
Test example 4
Anti-inflammatory action test on inflammatory factors:
(1) Raw264.7 cells in good culture were diluted to a concentration of 1X 10 6 cfu/mL；
(2) A24-well cell plate was prepared and the concentration was 1X 10 6 Transferring the cfu/mL Raw264.7 cells into a 24-well plate by using a pipette gun, adding 1mL of cells into each well, and culturing at 37 ℃ for 24h;
(3) The test contained 16 groups in total, a blank group (no sample), an LPS group (500. Mu.L of LPS added at 1. Mu.g/mL), a test group (500. Mu.L of sample solution added at examples 1-11 and comparative examples 1-2 containing 1. Mu.g/mL of LPS), and a positive control group (500. Mu.L of dexamethasone added at 0.1 mg/mL). Discarding the supernatant of Raw264.7 cell culture solution, adding the corresponding solution of each group, and culturing at 37 ℃ for 24h;
(4) And (3) sucking supernatant fluid, centrifuging, detecting the concentrations of inflammatory factors TNF-alpha and IL-1 alpha according to the test steps on an ELISA kit, carrying out parallel determination on each group for 3 times, and taking an average value. The results are shown in Table 4.
TABLE 4
From the data in table 4, it can be seen that: the acne-removing composition has very obvious inhibition effect on inflammatory factors TNF-alpha and IL-1 alpha, wherein lysozyme and nisin have synergistic effect on inhibiting the inflammatory factors.
The applicant states that the invention is illustrated by the above examples to provide an anti-acne composition containing antibacterial peptide, and a preparation method and application thereof, but the invention is not limited by the above examples, i.e. the invention is not necessarily dependent on the above examples to be implemented. It should be understood by those skilled in the art that any modifications of the present invention, equivalent substitutions of the raw materials of the product of the present invention, and the addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.
Claims (10)
1. An anti-acne composition containing antibacterial peptide, which is characterized by comprising a solid component and a liquid component which are packaged separately; the solid component comprises lysozyme and nisin; the liquid component comprises plant essential oil, solubilizer and water.
2. The anti-acne composition containing antibacterial peptide according to claim 1, wherein the solid component comprises 0.1-5 parts of lysozyme and 0.1-5 parts of nisin by weight; the liquid component comprises 0.01-0.2 part by weight of plant essential oil, 0.1-1 part by weight of solubilizer and 90-98 parts by weight of water;
preferably, the plant essential oil comprises any one or combination of at least two of eucalyptus essential oil, rosemary essential oil, thyme essential oil, angelica essential oil, sea buckthorn fruit essential oil or cinnamon essential oil;
preferably, the plant essential oil comprises a combination of eucalyptus essential oil, rosemary essential oil and thyme essential oil.
3. The anti-acne composition containing antibacterial peptide according to claim 1 or 2, wherein the liquid component further comprises glycyrrhizic acid derivative;
preferably, the glycyrrhizic acid derivative comprises any one of dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, diammonium glycyrrhizinate, disodium glycyrrhizinate, zinc glycyrrhetinate or glycyrrhetinate stearate or a combination of at least two of the two.
4. The anti-acne composition containing antibacterial peptide according to any one of claims 1 to 3, wherein the liquid component further comprises a keratolytic agent;
preferably, the keratolytic agent comprises any one of, or a combination of at least two of, tartaric acid, potassium methoxysalicylate, or hydroxyppinacolone retinoic acid ester, more preferably hydroxyppinacolone retinoic acid ester.
5. The anti-acne composition comprising antibacterial peptides according to any one of claims 1 to 4, wherein the liquid component further comprises a humectant;
preferably, the humectant comprises any one of, or a combination of at least two of, glycerin, propylene glycol, 1,3 butylene glycol or methyl propylene glycol;
preferably, the solid component further comprises betaine.
6. The anti-acne composition containing antibacterial peptide according to any one of claims 1 to 5, wherein the mass ratio of the solid component to the liquid component is (0.5-5) to (95-99.5);
preferably, the solid component comprises 0.1 to 5 parts of lysozyme, 0.1 to 5 parts of nisin and 90 to 99 parts of betaine by weight;
preferably, the liquid component comprises, by weight, 0.01-0.2 part of plant essential oil, 0.05-0.5 part of glycyrrhizic acid derivative, 0.01-0.1 part of cutin debonding agent, 2-10 parts of humectant, 0.1-1 part of solubilizer and 90-98 parts of water.
7. The anti-acne composition containing antibacterial peptide according to any one of claims 1 to 6, wherein the liquid component further comprises any one or a combination of at least two of chlorobutanol, phenoxyethanol, parabens or ethylhexyl glycerol, preferably chlorobutanol.
8. The preparation method of the anti-acne composition containing antibacterial peptides according to any one of claims 1 to 7, characterized in that the preparation method comprises the following steps:
uniformly mixing all the raw materials of the solid component; premixing plant essential oil and a solubilizer, and uniformly mixing the premixed plant essential oil and the solubilizer with other raw materials of liquid components; and independently packaging the solid component and the liquid component to obtain the product.
9. Method of use of an anti-acne composition comprising antibacterial peptides according to any of claims 1 to 7, characterized in that it is: and mixing the solid component and the liquid component which are independently packaged until the solid component is completely dissolved, and directly using the mixed liquid.
10. Use of the anti-acne composition containing the antibacterial peptide according to any one of claims 1 to 7 in preparation of skin care products or external medicinal preparations with anti-acne efficacy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210990576.1A CN115252460B (en) | 2022-08-18 | 2022-08-18 | Acne-removing composition containing antibacterial peptide, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210990576.1A CN115252460B (en) | 2022-08-18 | 2022-08-18 | Acne-removing composition containing antibacterial peptide, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115252460A true CN115252460A (en) | 2022-11-01 |
| CN115252460B CN115252460B (en) | 2024-07-09 |
Family
ID=83753710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210990576.1A Active CN115252460B (en) | 2022-08-18 | 2022-08-18 | Acne-removing composition containing antibacterial peptide, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115252460B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117481997A (en) * | 2023-11-29 | 2024-02-02 | 广东丸美生物技术股份有限公司 | Acne-removing repair composition containing recombinant collagen and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0374823A2 (en) * | 1988-12-21 | 1990-06-27 | HAARMANN & REIMER CORP. | Control of microbial growth with nisin/lysozyme formulations |
| KR20030046121A (en) * | 2001-12-05 | 2003-06-12 | 주식회사 태평양 | Acne skin composition comprising the nisin |
| CN1679504A (en) * | 2005-01-26 | 2005-10-12 | 安米 | Use of human lysozyme in cosmetics for treating acne |
-
2022
- 2022-08-18 CN CN202210990576.1A patent/CN115252460B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0374823A2 (en) * | 1988-12-21 | 1990-06-27 | HAARMANN & REIMER CORP. | Control of microbial growth with nisin/lysozyme formulations |
| KR20030046121A (en) * | 2001-12-05 | 2003-06-12 | 주식회사 태평양 | Acne skin composition comprising the nisin |
| CN1679504A (en) * | 2005-01-26 | 2005-10-12 | 安米 | Use of human lysozyme in cosmetics for treating acne |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117481997A (en) * | 2023-11-29 | 2024-02-02 | 广东丸美生物技术股份有限公司 | Acne-removing repair composition containing recombinant collagen and application thereof |
| CN117481997B (en) * | 2023-11-29 | 2024-05-17 | 广东丸美生物技术股份有限公司 | Acne-removing repair composition containing recombinant collagen and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115252460B (en) | 2024-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109498501B (en) | Polypeptide composition for removing acne and repairing skin | |
| EP2673288B1 (en) | Peptide for use in the treatment of skin conditions | |
| CN109010245B (en) | Acne-removing preparation | |
| KR20190053216A (en) | New cosmetic and / or functional food or dermatological use of yeast extract | |
| CN113693979B (en) | Oil-control acne-removing composition and application thereof | |
| KR101064904B1 (en) | Cosmetic composition for improving acne comprising natural extracts | |
| TWI750716B (en) | Topical composition and its use for preparation of composition for improving skin disease and dermatitis | |
| CN113855718A (en) | Artemisia apiacea extract and application thereof | |
| KR20150139298A (en) | Skin external composition containing hongguk extract for skin moisturizing | |
| CN108703908B (en) | Anti-acne and freckle-removing essence and preparation method thereof | |
| CN113679765A (en) | Cortex dictamni extract and application thereof | |
| CN115252460B (en) | Acne-removing composition containing antibacterial peptide, and preparation method and application thereof | |
| KR101499442B1 (en) | Skin external composition containing Tussilago Farfara and Hibiscus Mutabilis flower extract | |
| KR100994987B1 (en) | Cosmetic composition with the calming effect for skins | |
| KR101274811B1 (en) | Potent anti-acne composition containing perilla frutescens and/or lygodium japonicum extract | |
| WO2021143096A1 (en) | Whitening, acne-removing, blackhead-removing and anti-aging composition, and use and preparation thereof | |
| CN107028830B (en) | Medicine for preventing scar hyperplasia and preparation process thereof | |
| CN115414308B (en) | Acne-removing composition, preparation method and application | |
| CN114848721B (en) | Acne-removing composition containing plant extracts and application thereof | |
| US20240091132A1 (en) | Bertholletia excelsa extract and use thereof | |
| CN113797129B (en) | Antibacterial composition and preparation method and application thereof | |
| KR101398549B1 (en) | A composition for skin disease improvement comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient | |
| CN113116757B (en) | Collagenase inhibitor, moisturizing mask containing collagenase inhibitor and preparation method of moisturizing mask | |
| KR20090001268A (en) | Cosmetic composition comprising thyme oil for treating acne vulgaris | |
| CN117481997B (en) | Acne-removing repair composition containing recombinant collagen and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |